At a glance
- Originator Novartis
- Class Anti-ischaemics; Anticoagulants; Antiplatelets; Uricosurics; Vascular disorder therapies
- Mechanism of Action Thromboxane synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypertension; Ischaemic heart disorders; Thrombosis